Status:
COMPLETED
Influence of MMP on Brain AVM Hemorrhage
Lead Sponsor:
University of California, San Francisco
Conditions:
Arteriovenous Malformations
Cavernous Angiomas
Eligibility:
All Genders
13+ years
Phase:
PHASE1
Brief Summary
Brain vascular malformations, including arteriovenous malformations (AVM), cavernous malformations (CVM) and aneurysms, are a source of life-threatening risk of intracranial hemorrhage. The etiology a...
Detailed Description
* Doses will be randomized by the Pharmacy Department at UCSF for Doxycycline 100 mg/BID and Placebo BID. These will be prepared in blister-packs. * Depending on enrollment/surgery date, patients will...
Eligibility Criteria
Inclusion
- 13 years or older
- Female patients of child bearing age using barrier-type birth control
- Creatinine no greater than 2.0 mg/di
- Alanine aminotransferase (ALT) no greater than 2 times upper limit of normal
- WBC count at least 3,800/mm3
- BMI within 50% of normal
Exclusion
- Allergy to tetracycline
- Unstable medical illness (unstable angina, advanced cancer, etc) over the last 30 days
- Female patients of child-bearing age not using effective birth control (barrier)
- History of vestibular disease (except benign positional vertigo)
- History of noncompliance with treatment or other experimental protocols
- Patients taking other antibiotics
- History of systemic lupus erythematosis
- Patients who are immunocompromised Patients with clinically significant hepatic dysfunction
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00783523
Start Date
March 1 2008
End Date
December 1 2010
Last Update
August 9 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California
San Francisco, California, United States, 94143